Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?

Fidelity MSCI Health Care Index ETF (FHLC) is presented as the stronger long-term healthcare allocation versus SPDR S&P Pharmaceuticals ETF (XPH), with a 0.08% expense ratio versus 0.35%, 365 holdings versus 65, and a 1.2% dividend yield versus 0.5%. FHLC also had a smaller five-year maximum drawdown of 17.7% versus 30.9% for XPH, although XPH generated the higher one-year return (54.0% versus 29.2%) and higher five-year growth of $1,595 per $1,000 invested versus $1,331. The article favors FHLC for diversified, lower-cost exposure, while positioning XPH as a higher-risk, pharma-specific play tilted toward smaller drugmakers.

Analysis

The relevant exposure distinction is not “healthcare versus pharma,” but mega-cap metabolic/large-pharma beta versus equal-weighted development-stage drug beta. FHLC’s effective return driver is heavily concentrated in LLY, JNJ, and ABBV; its lower headline volatility can reverse if GLP-1 growth expectations or drug-pricing assumptions de-rate. XPH is a higher-beta expression of biotech financing conditions, FDA outcomes, and takeout premia, with substantially greater single-name clinical-trial dispersion despite its ETF wrapper.

The trailing performance gap likely embeds a meaningful rerating of smaller pharmaceutical companies rather than a durable fee-arbitrage opportunity. Over the next 1-3 months, lower real yields, accelerated M&A announcements, and favorable FDA decisions would extend XPH’s leadership; a risk-off move, higher long-end yields, or adverse trial/approval outcomes should produce materially larger downside than in FHLC. The relatively modest XPH asset base also raises liquidity and creation/redemption risk during a biotech drawdown, making it unsuitable as a large core allocation.

Contrarianly, the low-cost broad-healthcare narrative understates FHLC’s concentration risk and may be backward-looking after large-cap pharma’s GLP-1-led gains. For the next 6-18 months, FHLC has better downside resilience if small-cap biotech’s funding window closes, but XPH retains more convex upside if acquirers deploy balance sheets into late-stage endocrinology, rare disease, and peptide platforms. This is a relative-factor decision, not a sector-wide bullish signal.

Key Decisions for Investors

• No directional healthcare ETF trade solely on this comparison; the information content is low. Monitor the XPH/FHLC relative ratio for a 10-15% pullback from recent relative highs before considering a tactical long XPH position.
• For defensive healthcare exposure over 6-12 months, prefer long FHLC versus XPH: it reduces binary clinical and small-cap funding risk while retaining LLY, ABBV, and JNJ exposure. Reassess if LLY guidance weakens materially or if pharma pricing-policy risk broadens beyond Medicare negotiation headlines.
• For a 1-3 month pro-risk or M&A/FDA-calendar view, use a defined-risk long XPH / short FHLC pair rather than outright XPH. Size modestly given XPH liquidity; exit if real yields rise sharply or the pair loses 8-10%, as those conditions would likely signal renewed pressure on development-stage pharma valuations.
• Watch AMLX, CRNX, and MBX as read-through indicators rather than standalone recommendations: a cluster of positive clinical, regulatory, or acquisition outcomes would validate XPH’s equal-weight upside; adverse outcomes would demonstrate why FHLC’s apparent lower volatility is valuable.